《公司业绩》中国生物制药(01177.HK)半年纯利14.4亿人民币升5.8% 季度息2港仙
中国生物制药(01177.HK)公布截至今年6月底止中期业绩,营业额125.27亿元人民币(下同),按年升28.8%。纯利14.44亿元,按年升5.8%;每股盈利11.47分。派季度股息2港仙,连同已派发第一季度股息2港仙,首两季度合共派发股息每股4港仙。
撇除因收购北京泰德24%权益而新增可识别无形资产摊销费用,以及扣除权益投资及金融资产之未实现公允价值利润及亏损之影响後,基本盈利约 16.74亿万元,按年增约20.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.